Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Date:10/26/2010

NEW YORK, Oct. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.  The Zerenex Phase 3 clinical program is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA). The Company expects to complete the study and report top-line data before the end of the year.

The Zerenex Phase 3 short-term efficacy study is a multicenter, randomized, open-label clinical trial being conducted at 14 centers in the United States.  Approximately 150 patients have completed the 2-week washout period and have been randomized 1:1:1 to receive a fixed dose of Zerenex (1 gram, 6 grams or 8 grams per day) for a treatment period of 28 days.  The primary endpoint of the study is to demonstrate a dose response in the change of serum phosphorous from baseline (end of washout period) to end of the treatment period (day 28).

Dr. Julia Lewis, Professor of Medicine, Department of Nephrology, Vanderbilt University School of Medicine, and member of the Executive Committee of the Collaborative Study Group, is the Study Chair of the Zerenex Phase 3 registration program.  Dr. Samuel S. Blumenthal, Professor of Medicine at Medical College of Wisconsin, is the study's Co-Principal Investigator.

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are pleased by the rate of enrollment into this study, and we are grateful for the efficiency and dedication demonstrated by our clinical investigators.  We look forward to announcing the top-line data from this study before year-e
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
3. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
4. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
7. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Syneron Medical Ltd. (NASDAQ: ELOS ... that its new PicoWay® device has received CE Mark ... and pigmented lesions on any skin type. PicoWay is ... and 1064nm wavelengths, which utilizes Syneron,s proprietary PicoWay technology ... are trillionths of a second, known as picosecond pulses. ...
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , today announced that ... a special cash dividend of US$0.30 per ordinary share ... Company,s outstanding ordinary shares. The total expense for the ...
(Date:7/28/2014)...   Cardioxyl Pharmaceuticals, Inc. announced today the ... a novel potential treatment for acute decompensated heart failure ... has now initiated dosing of hospitalized patients with decompensated ... to further evaluate the drug,s safety and tolerability as ... I clinical trial evaluated the safety and tolerability of ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... plc (Nasdaq: JAZZ ) today announced that the ... Monday, February 27, 2011 at 4:30 p.m. EST/9:30 p.m. GMT. ... and review fourth quarter and full year 2011 financial results. ... accessed from the Investors section of the Jazz Pharmaceuticals, website ...
... PLEASANTON, Calif., Feb. 14, 2012  Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... Leerink Swann 2012 Global Healthcare Conference on Thursday, February ... Investor Relations and Business Development, will provide an update ...
Cached Medicine Technology:
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... of the peer-reviewed journal Lipids in Health and ... value—of Nordic Naturals triglyceride-form best-selling Ultimate Omega®/ProOmega®. Consistently ... according to SPINS scan data, the product was ... to other omega-3 products in the marketplace. The ...
(Date:7/29/2014)... “Our years of experience with ... to insulate their homes properly simply due to ... heat transfer and conduction,” Clean Crawls says in ... released an article explaining exactly how heat ... bills. , To contact Clean Crawls for their ...
(Date:7/29/2014)... Bethesda, Maryland (PRWEB) July 29, 2014 ... has been named a 2014 ASAE Power of ... Flu-Focused," a public awareness campaign to encourage everyone age ... annually. , ASAE recognized NFID for its power ... drive awareness and action among consumers and professionals about ...
(Date:7/29/2014)... 2014 “Approximately 18% of our population ... common chronic illnesses,” Western Washington Medical Group says in ... for those suffering from allergies to seek medical attention. ... care each year in the United States,” they continue. ... of life for themselves, rather than seeking the appropriate ...
(Date:7/29/2014)... 29, 2014 The Eleventh Annual Business ... concluded with the $10,000 prize being presented to Ambika ... ) , The 11th Annual Summit was held on ... who can bring innovative products and services for the ... to have had such excellent array of young companies ...
Breaking Medicine News(10 mins):Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 3Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2
... DOMA Vector and DOMA Technologies to provide Record Conversion Services to more ... the Pacific. DOMA will convert millions of veteran treatment records from ... service to our veterans while reducing cost. , ... Virginia Beach, Va. ...
... DIEGO, May 7 Brandes Investment Partners, L.P. ("Brandes") ... submitted to Mitsui Sumitomo Insurance Group Holdings, Inc. (the ... on the Tokyo Stock Exchange, a proposal for a ... at the Company,s upcoming annual meeting of shareholders. ...
... weathering recession at national ALFA conferencePHILADELPHIA , ... executives today expressed confidence in the state of ... the conclusion of a national conference here.The executives ... far better than other businesses because it had ...
... Mobilization Campaign Urges Congress to Make Health Reform Work ... Hospital at Stanford is joining the National ... to launch a grassroots mobilization campaign asking Congress and ... for children. "Our hospital is extraordinarily proud ...
... WASHINGTON, May 7 The following is ... of the American Health Care Association (AHCA), Dave Kyllo, ... (NCAL) and Alan G. Rosenbloom, President of the Alliance ... the Obama Administration,s commitment to creating new jobs and ...
... May 7 Acting in response to concerns about ... Hotels and Resorts (TM), a privately held operator ... North America and Europe, today announced a three-phase program ... and provide reassurance about the safety of its facilities.(logo: ...
Cached Medicine News:Health News:Veterans Administration Awards Small Business' $13 Million Contract to Digitize Veterans Health Records 2Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 2Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 3Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 4Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 5Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 6Health News:Senior Living Executives Optimistic About Future 2Health News:Lucile Packard Children's Hospital at Stanford to Raise Its Voice for Kids in Health Care Reform Debate 2Health News:Lucile Packard Children's Hospital at Stanford to Raise Its Voice for Kids in Health Care Reform Debate 3Health News:Joint Statement from AHCA, NCAL, and the Alliance on the Obama Administration's FY 2010 Budget 2Health News:Dolce Hotels and Resorts Initiates Program to Mitigate H1N1 Flu Risk 2
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
... The integration of Trabecular Metal ... proven implant design results in a ... not only meets surgeon demands for ... provides a wide variety of shell ...
The cementless BiHAPro cup combines proven concepts with the latest innovations in cementless THR....
Medicine Products: